

Amendments to the Claims

This listing of claim replaces all prior versions and listings of claims in the application.

Listing of Claims

1-36. (Cancelled)

37. (Currently Amended) A hydroxyethylstarch-protein conjugate, characterized in that the binding interaction between the hydroxyethylstarch molecule and the protein is a single covalent bonding which is the result of a coupling reaction between (i) the terminal aldehyde group of the hydroxyethylstarch molecule and (ii) a primary amino group of the protein to form a Schiff's base.

38-42. (Cancelled)

43. (Previously Presented) The conjugate as claimed in claim 37, characterized in that the covalent bonding is an amine linkage which is the result of a reduction of the Schiff's base to the amine.

44. (Previously Presented) The conjugate as claimed in claim 37, characterized in that the hydroxyethylstarch molecule has a molecular weight in the range from about 4 to about 1000 kDa.

45. (Previously Presented) The conjugate as claimed in claim 44, characterized in that the hydroxyethylstarch molecule has a molecular weight of about 4 to about 50 kDa.

46. (Previously Presented) The conjugate as claimed in claim 44, characterized in that the hydroxyethylstarch molecule has a molecular weight of about 70 to about 1000 kDa.

47. (Previously Presented) The conjugate as claimed in claim 46, characterized in that the hydroxyethylstarch molecule has a molecular weight of about 130 kDa.

48. (Previously Presented) The conjugate as claimed in claim 37, characterized in that the hydroxyethylstarch molecule has a degree of substitution of about 0.3 to about 0.7.
49. (Previously Presented) The conjugate as claimed in claim 37, characterized in that the hydroxyethylstarch molecule has a ratio of C₂ to C₆ substitution of from 8 to 12.
50. (Cancelled)
51. (Previously Presented) The conjugate as claimed in claim 37, characterized in that the protein has a regulatory or catalytic function, a signal transmitting or transport function or a function in the immune response or induction of an immune response.
52. (Previously Presented) The conjugate as claimed in claim 51, characterized in that the protein is selected from the group consisting of enzymes, antibodies, antigens, transport proteins, bioadhesion proteins, hormones and prohormones, growth factors and growth factor receptors, cytokines, receptors, suppressors, activators, and inhibitors.
53. (Previously Presented) The conjugate as claimed in claim 51, characterized in that the protein is α -, β - or γ -interferon, an interleukin, a serum protein, erythropoietin, myoglobin, hemoglobin, a plasminogen activator, BCGF, BDGF, EGF, FGF, NGF, PDGF, BDNF, CNTF, TGF- α , TGF- β , a colony-stimulating factor, a BMP, somatomedin, somatotropin, somatostatin, insulin, gonadotropin, α -MSH, triptorelin, prolactin, calcitonin, glucagon, a glucagon-like peptide, exendin, leptin, gastrin, secretin, an integrin, a hypothalamus hormone, a thyroid hormone, a growth hormone, LH, FSH, a pigmentary hormone, TNF- α or TNF- β , hirudin, a lipoprotein or apolipoprotein, an oligolysine protein, an RGD protein, a lectin or ricin, bee venom or a snake venom, an immunotoxin, ragweed allergen, antigen E, an immunoglobulin, or a receptor for one of these proteins.
54. (Previously Presented) The conjugate as claimed in claim 51, characterized in that the protein is an enzyme which is selected from the group consisting of an asparaginase,

arginase, arginine deaminase, adenosine deaminase, glutaminase, glutaminase-asparaginase, phenylalanine ammonia-lyase, tryptophanase, tyrosinase, superoxide dismutase, endotoxinase, catalase, peroxidase, kallikrein, trypsin, chymotrypsin, elastase, thermolysin, a lipase, uricase, adenosine diphosphatase, purine-nucleoside phosphorylase, bilirubin oxidase, glucose oxidase, glucodase, gluconate oxidase, galactosidase, glucocerebrosidase, glucuronidase, hyaluronidase, tissue factor, a tissue plasminogen activator, streptokinase, urokinase, an MAP kinase, DNase, RNase, and lactoferrin.

55. (Previously Presented) A pharmaceutical composition comprising an effective amount of a conjugate as claimed in claim 37 and a pharmaceutically acceptable carrier and, where appropriate, further excipients and active ingredients.
56. (Cancelled) ~~The use of a conjugate as claimed in claim 37 for the therapeutic or preventive treatment of humans or animals.~~
57. (Cancelled) ~~The use of a composition as claimed in claim 55 for the therapeutic or preventive treatment of humans or animals.~~
58. (Withdrawn – Currently Amended) A method for preparing a ~~hydroxyalkylstarch~~ hydroxyethylstarch-protein conjugate as claimed in claim 37 in which the binding interaction between the hydroxyethylstarch molecule and the protein is a single covalent bonding which is the result of a coupling reaction between (i) the terminal aldehyde group of the hydroxyethylstarch molecule and (ii) a primary amino group of the protein to form a Schiff's base, characterized in that [[a]] the coupling reaction is carried out in aqueous solution between the terminal aldehyde group, or a functional group derived from this aldehyde group by chemical reaction, of the hydroxyalkylstarch hydroxyethylstarch molecule and a functional primary amino group, which is able to react with this aldehyde group or functional group derived therefrom of the hydroxyalkylstarch molecule, of the protein, and the bonding resulting directly in the coupling reaction is modified where appropriate by a further reaction.

59. (Withdrawn) The method as claimed in claim 58, characterized in that the reaction medium of the coupling reaction is water or a mixture of water and an organic solvent, where the water content of the mixture is at least 80%.
60. (Cancelled) ~~The method as claimed in claim 58, characterized in that the terminal aldehyde group of the hydroxyalkylstarch molecule is converted by selective oxidation into the corresponding carboxyl functionality, and the latter is subsequently reacted under activating conditions in aqueous solution with a free amino group of the protein, so that the hydroxyalkylstarch molecule is linked to the protein by an amide linkage.~~
61. (Cancelled) ~~The method as claimed in claim 60, characterized in that the selective oxidation of the aldehyde group is carried out with iodine or metal ions in basic aqueous solution.~~
62. (Cancelled) ~~The method as claimed in claim 60, characterized in that the coupling reaction is carried out in the presence of a carbodiimide.~~
63. (Cancelled) ~~The method as claimed in claim 62, characterized in that the carbodiimide is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC).~~
64. (Withdrawn – Currently Amended) The method as claimed in claim 58, characterized in that the terminal aldehyde group of the ~~hydroxyalkylstarch~~ hydroxyethylstarch molecule is coupled to a ~~free~~ primary amino group of the protein to form a Schiff's base, and the formed Schiff's base is reduced to the amine, so that the ~~hydroxyalkylstarch~~ hydroxyethylstarch molecule is linked to the protein by an amine linkage.
65. (Withdrawn) The method as claimed in claim 64, characterized in that both coupling and reduction take place in aqueous solution.
66. (Withdrawn) The method as claimed in claim 64, characterized in that the reducing agent is sodium borohydride, sodium cyanoborohydride or an organic boron complex.

67. (Withdrawn) The method as claimed in claim 64, characterized in that the coupling and reduction reactions are carried out simultaneously.
68. (Cancelled) ~~A method for preparing hydroxyalkylstarch which is selectively oxidized at the terminal aldehyde group, characterized in that the hydroxyalkylstarch is reacted in a molar ratio of iodine to HAS of from 2:1 to 20:1 in basic aqueous solution.~~
69. (Cancelled) ~~The method as claimed in claim 68, characterized in that the molar ratio of iodine to HAS is about 5:1 to 6:1.~~
70. (Cancelled) The method as claimed in claim 68, characterized in that
- a) ~~an amount of hydroxyalkylstarch is dissolved in warm distilled water, and somewhat less than 1 mole equivalent of aqueous iodine solution is added,~~
 - b) ~~NaOH solution in a molar concentration which is about 5-15 times that of the iodine solution is slowly added dropwise, at intervals of a plurality of minutes, to the reaction solution until the solution starts to become clear again after the addition,~~
 - e) ~~somewhat less than 1 mole equivalent of aqueous iodine solution is again added to the reaction solution,~~
 - d) ~~the dropwise addition of the NaOH solution is resumed,~~
 - e) ~~steps b) to d) are repeated until approximately 5.5-6 mole equivalents of iodine solution and 11-12 mole equivalents of NaOH solution, based on the hydroxyalkylstarch, have been added,~~
 - f) ~~the reaction is then stopped, and the reaction solution is desalted and subjected to a cation exchange chromatography, and the reaction product is obtained by lyophilization.~~
71. (Cancelled) ~~The method as claimed in claim 70, characterized in that the aqueous iodine solution is an approximately 0.05-0.5N iodine solution.~~
72. (Cancelled) ~~The method as claimed in claim 70, characterized in that the molar concentration of the NaOH solution is about 10 times that of the iodine solution.~~

73. (Cancelled) ~~A method for preparing hydroxyalkylstarch which is selectively oxidized at the terminal aldehyde group, characterized in that the HAS is oxidized in aqueous alkaline solution with a molar excess of stabilized metal ions selected from Cu^{2+} ions and Ag^+ ions.~~

74-79. (Cancelled)